Form 4: MannKind CFO Christopher Prentiss Reports Acquisition of Restricted Stock Units

Christopher Prentiss, CFO of MannKind Corp, reports the acquisition of restricted stock units and common stock, with vesting schedules tied to performance and time-based criteria.

Summary

• On May 15, 2024, Christopher Prentiss, the Chief Financial Officer of MannKind Corporation, reported the acquisition of 103,600 shares of common stock and 129,000 shares of common stock.
• These acquisitions were related to restricted stock unit awards.
• Prentiss also acquired 158,000 performance-based restricted stock units.
• The vesting of these units is contingent on MannKind's total shareholder return (TSR) relative to the Russell 3000 Pharmaceutical & Biotechnology Index over a three-year period from July 1, 2024, to June 30, 2027.
• The number of shares delivered will vary from 0% to 300% of the target based on MannKind's TSR percentile ranking.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects standard executive compensation practices and aligns management interests with shareholder value. The performance-based vesting adds a positive element, incentivizing long-term growth.

Positives

• The acquisition of restricted stock units aligns the CFO's interests with those of the shareholders, incentivizing performance and value creation.

Risks

• The value of the performance-based restricted stock units is contingent on MannKind's TSR performance, which is subject to market volatility and industry-specific risks.

Future Outlook

The vesting of the performance-based restricted stock units is tied to MannKind's TSR relative to the Russell 3000 Pharmaceutical & Biotechnology Index over a three-year period, indicating a focus on long-term shareholder value.

Industry Context

The use of TSR-based vesting for executive compensation is a common practice in the pharmaceutical and biotechnology industry to align management incentives with shareholder returns.

Comparison to Industry Standards

• Many pharmaceutical and biotechnology companies use TSR as a key performance indicator for executive compensation.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize TSR metrics in their long-term incentive plans.
• The specific percentile rankings and payout percentages (0% to 300%) are within the typical range observed in the industry for performance-based equity awards.

Stakeholder Impact

• Shareholders may view the performance-based compensation as a positive sign, aligning management's interests with long-term value creation.
• Employees may be motivated by the potential for increased company performance and shareholder value.

Key Dates